MXPA06006740A - Prolinilarilacetamidas. - Google Patents

Prolinilarilacetamidas.

Info

Publication number
MXPA06006740A
MXPA06006740A MXPA06006740A MXPA06006740A MXPA06006740A MX PA06006740 A MXPA06006740 A MX PA06006740A MX PA06006740 A MXPA06006740 A MX PA06006740A MX PA06006740 A MXPA06006740 A MX PA06006740A MX PA06006740 A MXPA06006740 A MX PA06006740A
Authority
MX
Mexico
Prior art keywords
phenyl
amide
hydroxy
methyl
amino
Prior art date
Application number
MXPA06006740A
Other languages
English (en)
Spanish (es)
Inventor
Dieter Dorsch
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MXPA06006740A publication Critical patent/MXPA06006740A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
MXPA06006740A 2003-12-16 2004-11-26 Prolinilarilacetamidas. MXPA06006740A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10358814A DE10358814A1 (de) 2003-12-16 2003-12-16 Prolinylarylacetamide
PCT/EP2004/013509 WO2005058817A1 (de) 2003-12-16 2004-11-26 Prolinylarylacetamide

Publications (1)

Publication Number Publication Date
MXPA06006740A true MXPA06006740A (es) 2006-08-18

Family

ID=34683363

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06006740A MXPA06006740A (es) 2003-12-16 2004-11-26 Prolinilarilacetamidas.

Country Status (16)

Country Link
US (1) US7732481B2 (cg-RX-API-DMAC7.html)
EP (1) EP1697318B1 (cg-RX-API-DMAC7.html)
JP (1) JP4800969B2 (cg-RX-API-DMAC7.html)
KR (1) KR20060113729A (cg-RX-API-DMAC7.html)
CN (1) CN1894210A (cg-RX-API-DMAC7.html)
AR (1) AR046765A1 (cg-RX-API-DMAC7.html)
AT (1) ATE406350T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004299197B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0417630A (cg-RX-API-DMAC7.html)
CA (1) CA2549589A1 (cg-RX-API-DMAC7.html)
DE (2) DE10358814A1 (cg-RX-API-DMAC7.html)
ES (1) ES2310772T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA06006740A (cg-RX-API-DMAC7.html)
RU (1) RU2006125509A (cg-RX-API-DMAC7.html)
WO (1) WO2005058817A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200605841B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1818330A1 (de) * 2006-02-14 2007-08-15 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Prolinamide, deren Herstellung und deren Verwendung als Arzneimittel
PL2051975T3 (pl) * 2006-05-16 2013-01-31 Boehringer Ingelheim Int Podstawione prolinamidy, ich wytwarzanie oraz ich zastosowanie jako środków leczniczych
BRPI0813230A2 (pt) * 2007-06-28 2014-12-23 Novartis Ag Moduladores de calicreína 7
WO2011027888A1 (ja) * 2009-09-07 2011-03-10 大日本住友製薬株式会社 ジアミド-フェニル誘導体、またはその薬学的に許容される塩
CN109761957B (zh) * 2019-01-18 2020-05-19 西安交通大学 一种含有羟脯氨酸的化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
PL377633A1 (pl) 2003-04-03 2006-02-06 Merck Patent Gmbh Związki karbonylowe
WO2004087696A1 (de) * 2003-04-03 2004-10-14 Merck Patent Gmbh Pirazolidin-1,2-dicarbonsaüre-1-((phenyl)-amid)-2-((phenyl)-amid) derivate als koagulationsfaktor xa inhibitoren zur behandlung von thrombosen
DE102004014945A1 (de) * 2004-03-26 2005-10-13 Merck Patent Gmbh Prolinylderivate

Also Published As

Publication number Publication date
KR20060113729A (ko) 2006-11-02
WO2005058817A1 (de) 2005-06-30
AR046765A1 (es) 2005-12-21
ATE406350T1 (de) 2008-09-15
US7732481B2 (en) 2010-06-08
US20070185189A1 (en) 2007-08-09
AU2004299197A1 (en) 2005-06-30
DE502004007959D1 (de) 2008-10-09
JP2007513988A (ja) 2007-05-31
RU2006125509A (ru) 2008-01-27
BRPI0417630A (pt) 2007-03-27
CN1894210A (zh) 2007-01-10
AU2004299197B2 (en) 2010-08-05
ZA200605841B (en) 2007-10-31
DE10358814A1 (de) 2005-07-21
CA2549589A1 (en) 2005-06-30
ES2310772T3 (es) 2009-01-16
EP1697318B1 (de) 2008-08-27
JP4800969B2 (ja) 2011-10-26
EP1697318A1 (de) 2006-09-06

Similar Documents

Publication Publication Date Title
JP5015593B2 (ja) 血栓症の治療のための凝固因子XaおよびVIIaの阻害剤としての1−[(4−エチニルフェニル)]−2−[(フェニル)]−ピロリジン−1,2−ジカルボキサミド誘導体
JP4705015B2 (ja) カルボニル化合物
JP2008513387A (ja) カルボニル化合物を含む医薬およびこの使用
US20080081814A1 (en) Carbonyl Compounds Which Can be Used as Inhibitors of Coagulation Factor Xa
JP4732757B2 (ja) カルボキサミド
JP4990627B2 (ja) カルボキサミド誘導体
AU2005225489B2 (en) Prolinyl derivatives for treating thrombosis
AU2004299197B2 (en) Prolinylarylacetamides
JP4699985B2 (ja) カルボキサミド誘導体及びその第Xa因子の阻害剤としての使用
JP4567439B2 (ja) カルボン酸アミド
US20070161623A1 (en) Urea derivatives
US20060135515A1 (en) Heterocyclic amides and their use treating thromboembolic diseases and tumors
MXPA06006593A (en) Carboxamide derivatives
US20070265259A1 (en) Proline Derivatives
MXPA06008347A (en) Urea derivatives

Legal Events

Date Code Title Description
FA Abandonment or withdrawal